Global Sickle Cell Disease Treatment Market by Type (Hydroxyurea, Oxybryta, Adakveo, and others), By Application (Blood transfusion, Bone Marrow Transplants, and Pharmacotherapy and Others), By Route of Administration (Oral, Parenteral, and Others), By End-User, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2024-2032
- Published date: Oct 2023
- Report ID: 44935
- Number of Pages: 331
- Format:
-
keyboard_arrow_up
-
-
- Agios Pharmaceuticals
- Bristol-Myers Squibb
- CRISPR Therapeutics
- Editas Medicine
- Emmaus Life Sciences Inc.
- Medunic USA Inc.
- Novo Nordisk A/S Company Profile
- Vifor Pharma
- Other key Players
- settingsSettings
Our Clients
- 44935
- Oct 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
